Maze Therapeutics (MAZE) Competitors $10.23 +0.98 (+10.59%) As of 11:06 AM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsTrendsBuy This Stock MAZE vs. GPCR, SPRY, DYN, ARDX, OCUL, CALT, ADPT, IOVA, AMPH, and SNDXShould you be buying Maze Therapeutics stock or one of its competitors? The main competitors of Maze Therapeutics include Structure Therapeutics (GPCR), ARS Pharmaceuticals (SPRY), Dyne Therapeutics (DYN), Ardelyx (ARDX), Ocular Therapeutix (OCUL), Calliditas Therapeutics AB (publ) (CALT), Adaptive Biotechnologies (ADPT), Iovance Biotherapeutics (IOVA), Amphastar Pharmaceuticals (AMPH), and Syndax Pharmaceuticals (SNDX). These companies are all part of the "pharmaceutical products" industry. Maze Therapeutics vs. Structure Therapeutics ARS Pharmaceuticals Dyne Therapeutics Ardelyx Ocular Therapeutix Calliditas Therapeutics AB (publ) Adaptive Biotechnologies Iovance Biotherapeutics Amphastar Pharmaceuticals Syndax Pharmaceuticals Structure Therapeutics (NASDAQ:GPCR) and Maze Therapeutics (NASDAQ:MAZE) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, dividends, profitability, valuation, community ranking, institutional ownership, earnings, media sentiment and analyst recommendations. Does the MarketBeat Community prefer GPCR or MAZE? Structure Therapeutics received 26 more outperform votes than Maze Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Maze Therapeutics an outperform vote while only 88.89% of users gave Structure Therapeutics an outperform vote. CompanyUnderperformOutperformStructure TherapeuticsOutperform Votes3288.89% Underperform Votes411.11%Maze TherapeuticsOutperform Votes6100.00% Underperform VotesNo Votes Do institutionals and insiders hold more shares of GPCR or MAZE? 91.8% of Structure Therapeutics shares are owned by institutional investors. 9.4% of Structure Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Is GPCR or MAZE more profitable? Maze Therapeutics' return on equity of 0.00% beat Structure Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Structure TherapeuticsN/A -16.37% -15.68% Maze Therapeutics N/A N/A N/A Which has better earnings and valuation, GPCR or MAZE? Maze Therapeutics has higher revenue and earnings than Structure Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioStructure TherapeuticsN/AN/A-$89.62M-$0.79-34.47Maze Therapeutics$167.50M2.57N/AN/AN/A Do analysts rate GPCR or MAZE? Structure Therapeutics currently has a consensus target price of $81.29, suggesting a potential upside of 198.50%. Maze Therapeutics has a consensus target price of $25.67, suggesting a potential upside of 160.84%. Given Structure Therapeutics' higher possible upside, equities research analysts plainly believe Structure Therapeutics is more favorable than Maze Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Structure Therapeutics 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 3.00Maze Therapeutics 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 2 Strong Buy rating(s) 3.40 Does the media prefer GPCR or MAZE? In the previous week, Structure Therapeutics had 8 more articles in the media than Maze Therapeutics. MarketBeat recorded 10 mentions for Structure Therapeutics and 2 mentions for Maze Therapeutics. Structure Therapeutics' average media sentiment score of 0.96 beat Maze Therapeutics' score of 0.62 indicating that Structure Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Structure Therapeutics 4 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Maze Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryStructure Therapeutics beats Maze Therapeutics on 7 of the 13 factors compared between the two stocks. Get Maze Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for MAZE and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MAZE vs. The Competition Export to ExcelMetricMaze TherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$430.95M$2.98B$5.53B$7.99BDividend YieldN/A1.89%5.11%4.23%P/E RatioN/A30.6422.6518.64Price / Sales2.57500.06401.98103.80Price / CashN/A168.6838.1834.62Price / BookN/A3.206.754.30Net IncomeN/A-$72.35M$3.22B$248.44M7 Day Performance27.79%1.61%1.66%1.81%1 Month Performance-0.61%8.95%4.17%4.40%1 Year PerformanceN/A-22.19%16.17%5.97% Maze Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MAZEMaze TherapeuticsN/A$10.23+10.6%$25.67+150.9%N/A$448.03M$167.50M0.00121GPCRStructure Therapeutics2.2116 of 5 stars$23.74+0.4%$81.29+242.4%-31.5%$1.36BN/A-32.08136Upcoming EarningsNews CoverageSPRYARS Pharmaceuticals3.1313 of 5 stars$13.77-5.9%$31.00+125.1%+60.6%$1.35B$89.15M-27.0090Upcoming EarningsNews CoveragePositive NewsDYNDyne Therapeutics3.3281 of 5 stars$11.06-0.5%$47.46+329.1%-53.4%$1.26BN/A-3.11100Short Interest ↑ARDXArdelyx4.5603 of 5 stars$5.26+4.8%$10.61+101.7%-13.9%$1.25B$333.62M-32.8890Positive NewsOCULOcular Therapeutix3.4863 of 5 stars$7.71-2.4%$16.38+112.4%+75.1%$1.23B$63.72M-5.84230Upcoming EarningsNews CoveragePositive NewsCALTCalliditas Therapeutics AB (publ)N/A$40.00flat$39.25-1.9%N/A$1.19B$1.60B-21.62180ADPTAdaptive Biotechnologies4.1445 of 5 stars$7.90+0.1%$9.40+19.0%+180.9%$1.17B$178.96M-7.25790News CoveragePositive NewsIOVAIovance Biotherapeutics4.5644 of 5 stars$3.51+4.5%$18.22+419.2%-69.5%$1.15B$164.07M-2.36500Upcoming EarningsPositive NewsAMPHAmphastar Pharmaceuticals4.4978 of 5 stars$24.19+0.5%$43.50+79.8%-40.8%$1.15B$731.97M8.061,620Upcoming EarningsPositive NewsSNDXSyndax Pharmaceuticals3.6507 of 5 stars$13.33+0.2%$36.20+171.6%-33.0%$1.15B$23.68M-3.67110Upcoming EarningsPositive News Related Companies and Tools Related Companies Structure Therapeutics Competitors ARS Pharmaceuticals Competitors Dyne Therapeutics Competitors Ardelyx Competitors Ocular Therapeutix Competitors Calliditas Therapeutics AB (publ) Competitors Adaptive Biotechnologies Competitors Iovance Biotherapeutics Competitors Amphastar Pharmaceuticals Competitors Syndax Pharmaceuticals Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MAZE) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredIs he more powerful than Trump? Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredTrump and Buffett Are Quietly Leading America’s Gold RevivalThe “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has...Golden Portfolio | SponsoredThis isn’t a trade war. It’s worse…Investigative Journalist Bombhsell: The Curse on the U.S Dollar Depleted retirement accounts? Meme coin inv...Stansberry Research | SponsoredElon Musk’s next move from the Oval Office?No one is closer to President Trump than Tesla CEO Elon Musk. He's been dubbed Trump's "first buddy." Tr...Weiss Ratings | SponsoredTrump Treasure April 19Thanks to President Trump… A $900 investment across5 specific cryptos… Could gain 12,000% so quickly tha...Paradigm Press | SponsoredChina’s next move could destroy U.S. techThe U.S. fired the first shot with 145% tariffs. Apple relies heavily on Chinese production. Tesla needs Ch...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Maze Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Maze Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy MAZE Stock Free MAZE Stock Alerts